<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646941</url>
  </required_header>
  <id_info>
    <org_study_id>2020-025</org_study_id>
    <nct_id>NCT04646941</nct_id>
  </id_info>
  <brief_title>Diabetic Complications and Obstructive Sleep Apnea</brief_title>
  <acronym>DMOS</acronym>
  <official_title>Diabetic Complications and Obstructive Sleep Apnea in Type 2 Diabetic Patients: A Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To follow up the progress of chronic complications in T2DM patients who had undergone&#xD;
      anthropometric measurements, laboratory testing and standard overnight polysomnography&#xD;
      monitor from 2013 to 2018.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) is a common chronic sleep disorder and a frequent comorbidity&#xD;
      in patients with type 2 diabetes. There has been increasing recognition that OSA is highly&#xD;
      prevalent in persons with type 2 diabetes. This study is to explore the relationship between&#xD;
      OSA and the progress of chronic diabetes-related complications in type 2 diabetes who had&#xD;
      undergone anthropometric measurements, laboratory testing and standard overnight&#xD;
      polysomnography monitor from 2013 to 2018 in the Department of Endocrinology and Diabetes,&#xD;
      The First Affiliated Hospital of Xiamen University, Xiamen, China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the progress of diabetic complications</measure>
    <time_frame>From January 1, 2013 to December 31, 2020</time_frame>
    <description>Diabetic complications include diabetic microvascular complications, atherosclerotic cardiovascular disease(ASCVD), and Diabetic foot disease.&#xD;
Diabetic microvascular complications include diabetic nephropathy, diabetic retinopathy and diabetic neuropathy.&#xD;
Diabetic macrovascular complications refer to ASCVD, which is defined as coronary heart disease (CHD; acute and silent MI, and unstable angina), ischemic stroke, or peripheral artery disease (PAD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the new onset and types of tumor in T2DM patients</measure>
    <time_frame>From January 1, 2013 to December 31, 2020</time_frame>
    <description>the new onset and types of tumor in T2DM patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Diabetic Complications and Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>T2DM with OSA</arm_group_label>
    <description>Type 2 diabetes patients with obstructive sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM without OSA</arm_group_label>
    <description>Type 2 diabetes patients without obstructive sleep apnea</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>regular treatment</intervention_name>
    <description>The patients with or without OSA received regular hypoglycemic drugs.</description>
    <arm_group_label>T2DM with OSA</arm_group_label>
    <arm_group_label>T2DM without OSA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Type 2 diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Ageï¼š18-80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non type 2 diabetes mellitus&#xD;
&#xD;
          -  Preparation for pregnancy&#xD;
&#xD;
          -  Lactation patients&#xD;
&#xD;
          -  Patients with uncontrolled thyroid disease&#xD;
&#xD;
          -  Patients with severe cardiovascular disease&#xD;
&#xD;
          -  Patients with severe hepatic and renal insufficiency&#xD;
&#xD;
          -  Patients with oral and maxillofacial malformations and upper respiratory tract&#xD;
             malformations&#xD;
&#xD;
          -  Patients with pulmonary infection or COPD&#xD;
&#xD;
          -  Patients who are not willing to accept the questionnaire survey&#xD;
&#xD;
          -  Unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Changqin Liu, Dr.</last_name>
    <phone>+86-592-2137796</phone>
    <email>liuchangqin@xmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Zheng</last_name>
    <phone>+86-592-2137796</phone>
    <email>88126386@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Xiamen university</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changqin Liu, MD</last_name>
      <phone>+86-133 7698 6106</phone>
      <email>liuchangqin@xmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>diabetic complications</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The datasets used and/or analyzed in this cohort are available from the corresponding author on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

